Two-pronged approach could curb many cases of lung cancer

April 2, 2018, Children's Hospital Boston
These two lung samples are from mice prone to develop Kras-mutant non-small-cell lung cancer. The lungs of mouse on the left are filled with tumors, as expected. The lung on the right, whose Kras-mutant cells have lost the Irs1/Irs2 genes, lacks the insulin/IGF-1 signaling needed for growth and is virtually devoid of tumors. (In a later stage, the tumors develop a workaround that enables them to start growing again.) Credit: Clare (He) Xu, PhD, Boston Children's Hospital

Non-small-cell lung cancer, the most common type of lung cancer, is the leading cause of cancer death in the U.S. A new study suggests that about 1 in 4 cases, those driven by the KRAS oncogene, could be successfully treated with a combination of drugs that are already available clinically. The Boston Children's Hospital study was published today in the Proceedings of the National Academy of Sciences (PNAS).

For more than three decades, scientists have tried, with little success, to target the mutant KRAS oncogene with drugs. So instead, some researchers have tried to target related biological pathways.

One such pathway involves insulin and insulin-like growth factor-1 (IGF-1), which influence the uptake and release of nutrients and ultimately cell growth. But this pathway has not been definitively proven to fuel KRAS-driven cancers, and inhibitors of IGF-1 signaling have so far failed in clinical trials. In fact, a recent study in mice actually saw become more aggressive. However, this study targeted insulin/IGF-1 signaling only partially.

In the new study, researchers used genetic techniques to completely block insulin/IGF-1 signaling, providing the best test ground yet for studying the pathway's role in KRAS-driven . The model establishes that completely blocking the pathway can slow tumor growth—but also demonstrates the need for a second step to fully suppress it.

"Our study uses a robust way to block insulin/IGF-1 signaling and addresses a long-standing question in KRAS-mutant lung ," says Nada Kalaany, Ph.D., a researcher in Boston Children's Hospital's Division of Endocrinology and senior author of the paper. "When you use genetics, results can be more conclusive."

A new model of growth factors' effect in lung cancer

Kalaany's team created the new model by crossing two strains of mice: a well-established strain that models KRAS-driven lung cancer, and another strain that lacks insulin/IGF-1 signaling, previously developed by Morris White, Ph.D., of Boston Children's to study diabetes. This second model deletes two key genes, known as Irs1 and Irs2, that encode so-called "adaptor" proteins that are necessary for insulin/IGF-1 signaling (a discovery made by White in the 1980s).

The new, cross-bred mice provide the best model yet for studying insulin/IGF-1 signaling in lung cancer. The researchers went on to show that when both Irs1 and Irs2 are deleted in the lungs, insulin/IGF-1 signaling is eliminated and lung tumors are strongly suppressed.

"Almost all animals in this lung cancer model typically die within 15 weeks of KRAS activation," says Kalaany, who is also an assistant professor at Harvard Medical School and an associate member of the Broad institute of MIT and Harvard. "But the ones that lost both Irs1 and Irs2 were completely fine—we saw almost no tumors at 10 to 15 weeks."

This heat map shows levels of amino acids, the building blocks of protein, inside six non-small-cell lung tumor cell lines derived from Kras-mutant mice. Essential amino acids, which must be acquired from the diet, are listed in bold. At left, indicated in red, tumor cells from mice that carry the Irs1/Irs2 gene have higher levels of amino acids. At right are tumor cells from mice that have lost Irs1/Irs2, and consequently, insulin/IGF-1 signaling. As a result, these cells take up fewer amino acids and have strikingly lower levels, as shown in blue, and try to maintain growth by breaking down their own proteins to get amino acids. Credit: Clare (He) Xu, PhD, Boston Children's Hospital

Blocking a tumor workaround

Kalaany and her colleagues were excited by this result, since IGF-1 inhibitor drugs that block insulin/IGF-1 signaling as effectively as Irs1/2 deletion, are already available. But they also knew that tumor often figure out work-arounds.

"We decided to let the animals live longer, and sure enough, at around 16 weeks we started seeing some tumors," says Kalaany. "So then we asked, how were these tumor cells able to overcome loss of Irs1 and Irs2?"

Metabolic profiling revealed that tumor cells lacking Irs1/2 had significantly lower levels of essential amino acids, the building blocks of protein. Yet, outside the cells, amino acids were plentiful. The researchers found the same thing when they inhibited /IGF-1 signaling in human lung tumors.

"Growth factors like IGF-1 tell cells that nutrients are around, so when you suppress their signaling, the tumor cells don't take up the amino acids and think they are starved," Kalaany explains. "But we found that the cells can compensate for this and break down their own proteins to generate ."

A metabolic approach to cancer

It turns out protein breakdown can also be inhibited with existing drugs, such as chloroquine, which inhibits autophagy (literally, "self-eating") and is being used in several cancer drug trials, and bortezomib (Velcade), a so-called proteasome inhibitor that is used to treat multiple myeloma.

When Kalaany's team injected human lacking Irs1/2 into mice, tumors didn't grow as well. When they added inhibitors of protein breakdown, growth was almost completely suppressed.

Though both types of drugs, as well as IGF-1 inhibitors, are well tolerated, care would need to be taken in dosing any combination therapy to avoid toxicities, Kalaany says. Such therapies might also be safer if targeted to the lungs, she adds.

Like another recent study from Kalaany's lab on pancreatic cancer, the current study shows how targeting metabolism in cancer cells can be an effective weapon.

"Our work tries to identify metabolic dependencies and vulnerabilities in tumors," says Kalaany. "If we identify collaborators, we would love to have a clinical trial in combining IGF-1 inhibitors with autophagy inhibitors or proteasome inhibitors."

Explore further: A metabolic treatment for pancreatic cancer?

More information: He Xu el al., "Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis," PNAS (2018). www.pnas.org/cgi/doi/10.1073/pnas.1718414115

Related Stories

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

Scientists discover new therapeutic target for lung cancer driven by KRAS

July 28, 2016
UT Southwestern Medical Center researchers have identified a new way to target lung cancer through the KRAS gene, one of the most commonly mutated genes in human cancer and one researchers have so far had difficulty targeting ...

Researchers find a pathway that leads to resistance of aggressive brain tumor treatment

February 16, 2018
Glioblastoma multiforme is one of the most common and deadly brain tumors. Despite the initial responsiveness to state-of-the-art therapies, tumors virtually always become resistant and eventually recur. Researchers at Dartmouth's ...

Researchers develop new strategy to target KRAS mutant cancer

September 14, 2017
Although KRAS is one of the major oncogenes associated with aggressive cancers, drugs designed to block KRAS function have not been able to halt cancer progression in a clinical setting. Until now, KRAS has remained infamously ...

Editing genes one by one throughout colorectal cancer cell genome uncovers new drug target

September 27, 2017
Cancers driven by mutations in the KRAS gene are among the most deadly. For decades, researchers have tried unsuccessfully to directly target mutant KRAS proteins as a means to treat tumors. Instead of targeting mutant KRAS ...

Lung cancer clues found in downstream pathway

January 27, 2015
Despite the promise of the gene KRAS as a target for treating lung cancer, finding effective therapies has been challenging. Now researchers are traveling down the pathway to find what makes KRAS cancerous.

Recommended for you

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.